Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)

XELAVIRI compared sequential (Arm A) versus initial (Arm B) irinotecan in combination with fluoropyrimidine plus bevacizumab in patients with metastatic colorectal cancer, trial identification: NCT01249638. In the full analysis set of the study, non-inferiority of time to failure of strategy (TFS) was not shown. The present analysis was performed to evaluate the effect of gender on treatment outcome and tolerability.

Source: European Journal of Cancer - February 27, 2021 Category: Cancer & Oncology Authors: Kathrin Heinrich, Dominik P. Modest, Ingrid Ricard, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Ullrich Graeven, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Clemens Giessen-Jung, Arndt Stahler, Tags: Original Research Source Type: research